nach oben

Rheumatology International

Erschienen in:

01.01.2006 | Original Article

Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes

verfasst von: Michiaki Tanaka, Kayo Masuko-Hongo, Tomohiro Kato, Kusuki Nishioka, Hiroshi Nakamura

Erschienen in: Rheumatology International | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the study was to examine the effects of hyaluronan (HA) on human chondrocytes in terms of production of MMP-1 and RANTES. Chondrocytes were obtained from patients with osteoarthritis (OA) or femoral neck fracture (control). Chondrocytes in monolayer culture were treated with various molecular weights (1.2, 50, 800 and 1,900 kD) of HA and then stimulated with IL-1β. Production and expression of MMP-1 and RANTES were quantified by ELISA and real-time polymerase chain reaction (PCR). The response was blocked by anti-CD44 antibody. Production of MMP-1 was significantly suppressed by both 800- and 1,900-kD HA, while production of RANTES was suppressed by 1,900-kD HA. Expression of MMP-1 and RANTES mRNA was inhibited by 1,900-kD HA. Suppressive effects of HA on production of MMP-1 were canceled by treatment of anti-CD44 antibody. Higher CD44 expression was found in OA chondrocytes than in those of control. High-molecular-weight HA suppressed MMP-1 and RANTES production, mediated partly by CD44–HA interaction.

Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6:2397–2404PubMed

Termeer C, Sleeman JP, Simon JC (2003) Hyaluronan—magic glue for the regulation of the immune response? Trends Immunol 24:112–114CrossRefPubMed

McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW (1996) Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98:2403–2413PubMed

Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, Terao T (2002) CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer 102:379–389CrossRefPubMed

Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi SM, Hiramitsu T, Nakamura T (2003) Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol 30:1164–1172PubMed

Hamburger MI, Lakhanpal S, Mooar PA, Oster D (2003) Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 32:296–309CrossRefPubMed

Miltner O, Schneider U, Siebert CH, Niedhart C, Niethard FU (2002) Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis—a prospective clinical trial. Osteoarthritis Cartilage 10:680–686CrossRefPubMed

Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA (1997) Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum 40:2065–2074PubMed

Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K (2004) Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 22:293-299PubMed

10.

Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB (1995) Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 38:164–172PubMed

11.

Yuan GH, Masuko-Hongo K, Sakata M, Tsuruha J, Onuma H, Nakamura H, Aoki H, Kato T, Nishioka K (2001) The role of C–C chemokines and their receptors in osteoarthritis. Arthritis Rheum 44:1056–1070PubMed

12.

Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T (1992) The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions 37:155–156PubMed

13.

Akatsuka M, Yamamoto Y, Tobetto K, Yasui T, Ando T (1993) In vitro effects of hyaluronan on prostaglandin E2 induction by interleukin-1 in rabbit articular chondrocytes. Agents Actions 38:122–125PubMed

14.

Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M, Tanaka S (1996) Hyaluronic acid increased proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J Pharm Exp Ther 277:1672–1675

15.

Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K et al (1986) Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29:1039–1049PubMed

16.

Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M (1997) Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24:365–71PubMed

17.

Geuerassimov A, Zhang Y, Cartman A, Rosenberg LC, Esdaile J, Fitzcharles MA, Poole R (1999) Immune responses to cartilage link protein and the G1 domain of proteoglycan aggrecan in patients with osteoarthritis. Arthritis Rheum 42:527–533CrossRefPubMed

18.

Nakamura H, Yoshino S, Tsuruha J, Nishioka K (1999) T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cart 7:401–402CrossRefPubMed

19.

Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Am Rheum Dis 59:455–461CrossRef

20.

Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 17(290):3115–3121CrossRef

21.

Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T (2004) Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 50:516–525CrossRefPubMed

22.

Liu D, Sy MS (1997) Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. J Immunol 15(159):2702–2711

23.

Culty M, Nguyen HA, Underhill CB (1992) The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 116:1055–1062CrossRefPubMed

24.

Flannery CR, Little CB, Hughes CE, Caterson B (1998) Expression and activity of articular cartilage hyaluronidases. Biochem Biophys Res Commun 29(251):824–829CrossRef

25.

Turley EA, Noble PW, Bourguignon LY (2002) Signaling properties of hyaluronan receptors. J Biol Chem 15(277):4589–4592CrossRef

Titel: Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes
verfasst von: Michiaki Tanaka
Kayo Masuko-Hongo
Tomohiro Kato
Kusuki Nishioka
Hiroshi Nakamura
Publikationsdatum: 01.01.2006
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 3/2006
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-004-0547-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports

Risk of contralateral avascular necrosis (AVN) after total hip arthroplasty (THA) for non-traumatic AVN

Successful treatment of chronic tophaceous gout with infliximab (Remicade)

Anti-TNF-α antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study

Macrophage-like synoviocytes display phenotypic polymorphisms in a serum-free tissue-culture medium

Soluble CD21 in sera and synovial fluid of arthritic patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Update Innere Medizin